NCT04706364

Brief Summary

Individuals with autism spectrum disorders (ASD) commonly experience variances in tactile behaviors, such as hypersensitivity to light touch stimuli, altered texture discrimination, and hyporesponsivity to pain. Researchers aim to investigate the somatosensory sensitivity and sensorimotor integration utilizing novel, objective behavioral assays and TMS. The main purpose is to study brain plasticity (the changes that occur in the brain through experience) in individuals with autism spectrum disorders.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 10, 2019

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

January 11, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 12, 2021

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
Last Updated

November 5, 2021

Status Verified

November 1, 2021

Enrollment Period

2.9 years

First QC Date

January 11, 2021

Last Update Submit

November 4, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Textured novel object recognition test (NORT) and mechanical detection threshold (MDT) with von Frey hairs

    To assess the validity of tactile prepulse inhibition (PPI) and other quantitative somatosensory assessments as potential biomarkers for somatosensory dysfunction in children with ASD. These metrics will provide a valuable comparison to the more-quantitative physiological measures by PAS and PPI.

    3 years

  • Somatosensory temporal discrimination threshold (STDT) and PAS-induced modulation of motor-evoked potentials (MEPs)

    To assess the validity of PAS-induced modulation of corticospinal excitability as a neurophysiologic biomarker for somatosensory dysfunction in children with ASD.

    3 years

Study Arms (2)

Autism Spectrum Disorder (ASD)

Individuals diagnosed with an Autism Spectrum Disorder

Behavioral: Neuropsychological TestingGenetic: (Optional) Saliva CollectionDevice: Sensory TestingDevice: Electroencephalogram (EEG)Device: Transcranial Magnetic Stimulation

Healthy Control

Typically developing individuals without a history of autism

Behavioral: Neuropsychological TestingGenetic: (Optional) Saliva CollectionDevice: Sensory TestingDevice: Electroencephalogram (EEG)Device: Transcranial Magnetic Stimulation

Interventions

Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.

Autism Spectrum Disorder (ASD)Healthy Control

The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes. Genetic testing is funded by Boston Children's Hospital.

Autism Spectrum Disorder (ASD)Healthy Control

Three different tests will be completed: the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold). Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist). The second sensory visit will be another version of the PPI testing involving hearing and sound.

Autism Spectrum Disorder (ASD)Healthy Control

A cap will be placed on the participants head that will be filled with electrodes (small discs). The EEG will allow investigators to measure how the brain reacts to the sensory testing.

Autism Spectrum Disorder (ASD)Healthy Control

Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex. There will be two - four identical TMS testing visits.

Autism Spectrum Disorder (ASD)Healthy Control

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Children diagnosed with an Autism Spectrum Disorder (ASD), as well as controls.

You may qualify if:

  • For ASD group:
  • Clinical diagnosis of a disorder on the autism spectrum according to:
  • DSM-IV or DSM 5 criteria
  • IQ\>70 (as determined by the Abbreviated Stanford-Binet IQ)
  • For the Control group:
  • No history of ASD or other developmental delay
  • No history of ASD or other developmental delay in first-degree relatives.
  • No history of clinical diagnosis of an anxiety disorder

You may not qualify if:

  • Both ASD and Control groups:
  • Intracranial pathology, cerebral palsy, history of severe head injury, or syndromic dysmorphology
  • History of fainting spells of unknown or undetermined etiology that might constitute seizure
  • History of seizure or epilepsy
  • Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency
  • Metal implants (excluding dental fillings) or devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible MD
  • Substance abuse or dependence within the past six months
  • Chronic treatment with prescription medications that decrease cortical seizure threshold
  • Peripheral neuropathy, as determined by the study MD during neurologic exam
  • For the Control group:
  • For control participants' medical history will be reviewed for diagnoses of neurologic or psychiatric disease. If in the judgment of the investigator, the condition, e.g., depression, is well-controlled with stable medications, and does not include abnormalities of the sensory motor systems, they may be included in the study. Control participants will be excluded from taking part in the study if they have a 1st degree relative with ASD.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Boston Children's Hospital

Boston, Massachusetts, 02115, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Saliva sample for genetic testing (optional)

MeSH Terms

Conditions

Autism Spectrum Disorder

Interventions

Neuropsychological TestsElectroencephalographyTranscranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Psychological TestsBehavioral Disciplines and ActivitiesDiagnostic Techniques, NeurologicalDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosisMagnetic Field TherapyTherapeutics

Study Officials

  • Alexander Rotenberg, MD, PhD

    Alexander.Rotenberg@childrens.harvard.edu

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Neurology

Study Record Dates

First Submitted

January 11, 2021

First Posted

January 12, 2021

Study Start

June 10, 2019

Primary Completion

May 1, 2022

Study Completion

May 1, 2022

Last Updated

November 5, 2021

Record last verified: 2021-11

Locations